Replimune Group, Inc. (NASDAQ:REPL) director Robert Coffin has sold a total of 11,464 shares of the company's common stock, realizing over $74,000 from the sale. The transactions took place on May 16, 2024, with the shares being sold at an average price of $6.47 each.
The sale was part of a "sell to cover" strategy associated with the partial vesting of Coffin's Restricted Stock Units (RSUs). This type of transaction is typically executed to cover tax withholding obligations and is often set up in advance through an irrevocable provision in the award agreements under which the RSUs are granted. It is important to note that such sales do not necessarily reflect a change in an insider's view of the company's prospects but are rather a common practice for handling tax implications of vested equity.
The shares sold by Coffin were traded within a price range of $6.46 to $6.56, as per the weighted average disclosed in the filing. Post-transaction, Coffin continues to hold a significant amount of Replimune stock, retaining 1,821,872 shares after the reported sale.
Investors and followers of insider transactions can request detailed information about the specific prices of shares sold within the reported range if needed.
Replimune Group, Inc. specializes in biological products, operating within the life sciences sector, and is incorporated in Delaware. The company's business address is located in Woburn, MA.
InvestingPro Insights
Replimune Group, Inc. (NASDAQ:REPL) has faced a challenging market recently, as evidenced by the significant decline in its share price. The company's stock has taken a substantial hit, with a -69.66% total return over the past year, reflecting investor concerns and market conditions. This downward trend is further highlighted by the stock trading near its 52-week low, at only 23.94% of its highest value in the same period.
Analyzing the company's financial health, Replimune's market capitalization stands at $364.81M, which may attract certain investors looking for small-cap biotech companies with potential for growth. However, with a negative P/E ratio of -1.81, the company is not currently generating profits, a fact that is underscored by the InvestingPro Tip that analysts do not expect the company to be profitable this year. This is consistent with the company's last twelve months' performance as of Q4 2024, where it reported an operating income of -$232.85M.
For investors interested in further insights and analysis, there are additional InvestingPro Tips available for Replimune Group, Inc., which can be accessed through the dedicated InvestingPro page. These tips provide a deeper dive into the company's financials and market performance, offering a clearer picture of its potential investment value. Furthermore, for those considering a subscription, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.